KNSA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Kiniksa Pharmaceuticals Ltd · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 74.34 USD
18.3% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 45.6% above the Trend Line and sits at 83.2% of its 52-week range. The latest completed week returned 18.3%, after a 15.2% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is bearish with 36/100 conviction, while the latest news-sentiment score is 59/100. Near-term considerations: earnings are due in 3d.

Setup score 77 out of 100
Latest Close 74.34 USD 31 Jul 2026
1W Return 18.3% latest completed week
4W Return 15.2% short-term follow-through
12W Return 26.9% quarterly tape
Trend Breadth 100.0% 52 of 52 weeks active
Volume Ratio 1.9x vs 13-week average
What is working
  • The trend backdrop is active with a 64-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 14 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 18.3% Latest completed week; four-week move 15.2%. Indicator stack 100/80 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bearish 36/100 conviction; expected move 9.2%. News sentiment 59/100 57 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 45.6% above the Trend Line and sits at 83.2% of its 52-week range. The latest completed week returned 18.3%, after a 15.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.9x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9012-week average 0.88

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.90Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers1414 reversal markers

No recent accumulation markers. 14 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 15.2% over four weeks, 26.9% over 12 weeks, and 132.5% over one year. The current trend has remained active for 64 consecutive weeks.

Performance by holding period

1W18.3%
4W15.2%
12W26.9%
26W69.3%
52W132.5%
Active trend streak64 weeks
Active weeks in one year52
Trend breadth100.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.32Latest activity-pressure read.
Pressure change79.5%Four-week change in activity pressure.
Leadership50.48Latest relative-leadership reading.
RS change56.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength51/100Blend of value, momentum, and quality. Underlying universe rank 50; rank 1 is best.
Value3/100Relative valuation strength. Underlying universe rank 98; rank 1 is best.
Quality94/100Profitability and accounting quality. Underlying universe rank 7; rank 1 is best.
Momentum97/100Medium-term price momentum. Underlying universe rank 4; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework24/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
66.2x
Price divided by trailing earnings.
Price / sales
6.4x
Market value relative to trailing revenue.
EV / EBITDA
43.2x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
3.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
54.6%
Gross profit retained from each unit of revenue.
Operating margin
14.1%
Operating profit retained from revenue.
Free-cash-flow margin
22.2%
Free cash flow generated from revenue.
Return on invested capital
17.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
56.7%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
277.9%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.8%
Net share repurchases relative to market value.
Shareholder yield
-0.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

KNSA shows bearish options pressure with a 36/100 conviction score, put-call volume ratio of 2.42, expected move of 9.2%, and Sharemaestro trend signal active.

Conviction36/100
Expected move9.2%
Put/call volume2.42
Pressure-32
Speculation9
Volatility68
Trend agreement55
Open options detail
Insider activity17 / 3

17 acquisitions and 3 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment59/100

Weighted news tone is neutral across 57 relevant articles.

27 positive · 30 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move9.2%Nearest-chain priced movement where available.
52-week drawdown-10.4%Distance below the 52-week high.
13-week volatility7.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+29.2%Week of 1 May.
Worst week-9.1%Week of 29 May.
Latest week+18.3%Week of 31 Jul.

Shape of recent returns

Strong gains10
Modest gains4
Flat weeks0
Modest losses7
Sharp losses5
Recent vol7.1%13-week weekly-return volatility.
Base vol6.2%52-week weekly-return volatility.
Up/down split32/20Count of positive and negative weeks in the 52-week window.
Average skew5.1% / -3.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape76/100

Trend, activity pressure, participation, and risk combine to a 76/100 tape read.

 Indicator analysis76/100

Latest 12-week confirmation: trend 12/12, activity pressure 10/12, relative leadership 11/12.

Activity pressure 0.90; 14 reversal markers Factors60/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 76; Small Cap Core rank 99 SVQF24/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 549.5 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options48/100

KNSA shows bearish options pressure with a 36/100 conviction score, put-call volume ratio of 2.42, expected move of 9.2%, and Sharemaestro trend signal active.

Bearish · Put-side pressure · Expected move 9.2% Sentiment59/100

Weighted news tone is neutral across 57 relevant articles.

Sei Investments Co. Has $13.68 Million Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA Insiders17 / 3

17 acquisitions and 3 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202674.34 USD18.3%51.07 USD29.37 USD1.3250.487.1MOn
24 Jul 202662.84 USD-1.7%49.99 USD29.01 USD1.2329.642.3MOn
17 Jul 202663.95 USD0.8%49.29 USD28.73 USD1.3031.432.7MOn
10 Jul 202663.44 USD-1.7%48.60 USD28.42 USD1.0826.353.8MOn
3 Jul 202664.53 USD9.0%47.87 USD28.10 USD0.7332.194.2MOn
26 Jun 202659.20 USD7.4%47.11 USD27.78 USD0.2823.729.9MOn
19 Jun 202655.11 USD6.2%46.56 USD27.49 USD-0.1511.012.4MOn
12 Jun 202651.89 USD7.2%46.10 USD27.23 USD-0.087.942.4MOn
5 Jun 202648.42 USD0.1%45.72 USD27.00 USD0.253.592.7MOn
29 May 202648.38 USD-9.1%45.38 USD26.79 USD0.71-0.832.4MOn
22 May 202653.24 USD-5.8%45.01 USD26.57 USD1.1512.712.6MOn
15 May 202656.51 USD-3.6%44.53 USD26.32 USD0.8221.842.2MOn
8 May 202658.60 USD6.0%43.93 USD26.04 USD0.3527.033.2MOn
1 May 202655.27 USD29.2%43.24 USD25.75 USD0.0227.497.5MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.